Invion Ltd has released a press release.
Activities Report and Appendix 4C
Filed with ASX ·
6ix hasn’t read this filing yet.
Story so far
Earlier from Invion
- Invion Doses First Patient in Phase I/II Skin Cancer Trial
- Consolidation/Split - IVX
- Invion Limited (ASX: IVX) Prostate Cancer Trial Results
- Ph 2 Prostate Cancer Results Strong Safety and 40% Response
- Invion secures funding through an institutional placement
Later from Invion
- Oesophageal Cancer Collaboration and Funding Agreement
- Completion Of Placement to Accelerate Clinical Programs
- Share Purchase Agreement Termination and Tranche Repayment
- Appendix 4C and Quarterly Activities Report - March 2025
- Dosing of 1st Six Patients in Phase I/II Skin Cancer Trial
Follow Invion into a list and get an email when it puts out news.
Follow Invion